On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Over the last 30 years, there has been very little improvement in the age of diagnosis of Duchenne muscular dystrophy. Despite numerous advocacy organizations’ efforts and high profile campaigns to raise public and professional awareness of this condition, a persistent diagnostic odyssey remains.
In recent years, new therapeutic approaches aimed at restoring dystrophin expression have been developed and approved, while others are in clinical trials, including gene therapy.
Newborn screening for DMD has been piloted in a number of centers around the world. There is a renewed interest and support for the case of NBS for DMD as demonstrated by the recent submission of a nomination package to add Duchenne to the Recommended Uniform Screening Panel (RUSP) in the USA.
